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Abstract
Genomics is a promising tool that is becoming more widely available to improve the care and
treatment of individuals. While there is much assertion, genomics will most certainly require the
use of clinical decision support (CDS) to be fully realized in the routine clinical setting. The
National Human Genome Research Institute (NHGRI) of the National Institutes of Health recently
convened an in-person, multi-day meeting on this topic. It was widely recognized that there is a
need to promote the innovation and development of resources for genomic CDS such as a CDS
sandbox. The purpose of this study was to evaluate a proposed approach for such a genomic CDS
sandbox among domain experts and potential users. Survey results indicate a significant interest
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and desire for a genomic CDS sandbox environment among domain experts. These results will be
used to guide the development of a genomic CDS sandbox.

Keywords
Clinical Decision Support Systems; Genomics; Medical genetics; Health information technology;
Personalized medicine

1. Introduction
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Genomics will have a considerable impact on the future of medicine by personalizing care
and treatment of patients.1 However, the application of genomics to routine clinical care will
be limited by physician proficiency in genetics, lack of clinical genetics expertise, and most
importantly the complex nature of genomic information. Clinical decision support (CDS)
has been proposed as a feasible solution to overcome these challenges.2 CDS provides
clinicians, patients, and other healthcare stakeholders with pertinent knowledge and personspecific information, intelligently filtered or presented at appropriate times, to enhance
health and healthcare.3 CDS can help clinicians manage the complexities of genetics at the
point of care and support genetically-guided medicine.2 However, literature and practical
implementations of genomic CDS, in particular whole-genome sequence (WGS)
information, are currently very nascent.4–6 Before genomic CDS is mature enough to be
implemented in routine clinical care, there is much to consider such as health IT
architectures and integration, genomic knowledge bases, managing genomic data and its
changing interpretations, data models and standards. To guide genomic CDS development,
genomics and CDS experts have put forward key technical requirements and
considerations.7,8 See Figure 1. Following these technical desiderata, researchers have
started developing and exploring novel genomic CDS solutions.9–12
1.1 NIH genomic CDS conference
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Recognizing that more work is necessary to fully support genomic CDS on a widespread
scale, the National Human Genome Research Institute (NHGRI) convened a meeting on
"Genomic Clinical Decision Support: Developing Solutions for Clinical and Research
Implementation" in Bethesda, MD in October of 2014.13 This meeting convened key thought
leaders in genomic medicine implementation and application of CDS to (1) compare current
state with ideal state of genomic CDS in order to define gaps and strategies to close the gaps;
(2) identify and engage US and international health IT initiatives that would support
recommended strategies; and (3) define a prioritized research agenda for genomic CDS. A
notable outcome was the need for a genomic CDS sandbox to promote the development,
evaluation, and testing of genomic CDS.
1.2 Genomic CDS sandbox
During the conference, many issues were highlighted that could be addressed with a
genomic CDS sandbox. For example, with a standardized genomic CDS sandbox,
researchers will be able to:
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1.2.1 Develop and test genomic CDS rules and algorithms—Genomic CDS is
still in its infancy, many rules and algorithms for genomics have yet to be developed and
tested, and there is still much to be learned. A genomic CDS sandbox provides an ideal
environment to develop and test new rules and algorithms, prior to deployment in a real
health IT system. Sandbox environments are often part of proprietary EHRs, however they
have limited flexibility and control for what users can test or change. In contrast, the
proposed genomic CDS sandbox will allow several EHR and health IT components to be
used and tested independent of proprietary systems A CDS sandbox environment also
promotes rapid development, allowing for success or failure of novel CDS to occur early and
often. Furthermore, non-technical domain experts such as pharmacists and clinicians could
utilize the sandbox to develop CDS rules.
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1.2.2 Design and implement novel architectural approaches—Current CDS
approaches are not able to meet the demands of genomic CDS for many reasons.14,7
Architectural approaches need to support disparate data sources and health IT components to
effectively provide genomic CDS.15 A genomic CDS sandbox allows these architecture
approaches to be developed, evaluated, and refined.
1.2.3 Identify gaps in standards and technologies—To promote interoperability
and widespread adoption, genomic CDS should leverage current CDS and genomic CDS
standards (Desiderata #12). Oftentimes gaps in health IT standards and capabilities arise
during implementation, causing developers to implement non-standard solutions. With a
genomic CDS sandbox, such issues can be identified and addressed in the preimplementation phase, allowing informatics professionals to address standards issues
through the proper channels in a formal way.
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1.2.4 Conduct usability and human factors research—Usability and human
factors often contributes to the success or failure of a CDS intervention.16 As genomic CDS
is a new technology, human factors research is critical. However, production EHR systems is
not the best place for usability and human factors research. A genomic CDS sandbox would
be an ideal environment to create and test innovate user interfaces for genomic CDS, that
can ultimately improve the usability and success of genomic CDS.
1.3 Genomic CDS sandbox description
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A sandbox environment is a collaborative, non-production, development environment in
which novel concepts for emerging technologies can be explored with no risk to clinical
systems. Sandbox domains have proven useful in other informatics fields.17,18 The ultimate
goal of a genomic CDS sandbox is to provide a common platform which allows domain
experts and knowledge translation experts to build and test shareable CDS knowledge base
for genomics. Specifically to meet the requirements described above, namely to: 1) develop
and test genomic CDS rules and algorithms, (2) design and implement novel architectural
approaches, (3) identify gaps in standards and technologies, and (4) conduct usability and
human factors research.
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To accomplish this, the proposed genomic CDS sandbox would be implemented as an opensource, freely available and distributable virtual machine (VM). The proposed sandbox
would consist of several open source health IT and genomics applications (such as
OpenMRS, VistA, OpenCDS, SMARTapps), installed and preconfigured on the VM. These
components would include synthetic clinical and genomic data, with fully functional
genomic CDS examples available to test and modify. Additions and modifications to the
genomic CDS sandbox would be limited to the user's virtual environment, but users would
be able to share their work with other users. If appropriate, enhancements can be added to
the default genomic CDS sandbox. With this approach, a community of technical and
clinical domain experts could collaboratively develop and refine genomic CDS solutions and
approaches. Additionally, by preconfiguring these applications and distributing them using a
VM, it reduces the need for specialized technical expertise to set up and run such
components. Additionally the system would include sufficient training resources to help
non-technical users build and test genomic CDS approaches. Nevertheless, the intended end
users of the genomic CDS sandbox could be both technical and non-technical domain
experts. As this genomic CDS sandbox is a community-driven, open source project, any
intellectual property generated using the product will belong to the user.
1.4 Purpose of study
To guide the design and development of a genomic CDS sandbox, we engaged potential
genomic CDS sandbox end users to assess their level of interest and to determine desired
features. Specifically, we sought to (1) validate the proposed genomic CDS sandbox
approach among domain experts; (2) identify desired use cases; and (3) determine the best
approach for building a community of users.
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2. Methods
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Using REDCap,19 we distributed an online survey among potential end users of a genomic
CDS sandbox. An initial set of 26 Likert-scale questions were developed based on the
perceived need of genomic CDS sandbox derived from discussions and comments at the
NHGRI meeting. In January 2015, the initial set of questions were distributed to an advisory
panel consisting of domain experts in CDS and genomics who attended the NHGRI meeting
(see authors). The advisory panel commented and helped revise the questions incorporated
into the final survey by AA and BMW. Based on feedback from the advisory panel, the final
survey consisted of 22 questions divided into four parts: (1) involvement with genomics and
the CDS domain; (2) validation of the genomic CDS sandbox approach; (3) usage of the
genomic CDS sandbox; and (4) building a genomic CDS sandbox community. The survey
text and questions can be found in Appendix A.
To obtain a diverse representation of domain experts, we distributed the survey to a variety
of CDS and genomics professional organizations. Participants included members of the HL7
Clinical Genomics Work Group, the HL7 CDS Work Group, the AMIA Genomics Work
Group, the AMIA CDS Workgroup, the ClinGen project, the Clinical Pharmacogenetics
Implementation Consortium (CPIC), the Clinical Sequencing Exploratory Research (CSER)
consortium EHR working group, the Pharmacogenomics Knowledge Base (PharmGKB), the
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Pharmacogenomics Research Network (PGRN), the EHR Integration (EHRI) and
Phenotyping workgroups of the Electronic Medical Records and Genomics Network
(eMERGE), and NHGRI Genomic Medicine meeting attendees. Survey responses were
collected in February 2015. The survey was distributed to roughly 600 potential participants
via email lists and blog postings for each workgroup or consortia.

3. Results

Author Manuscript

We initially received 54 survey responses, after exclusion of incomplete responses, a final
sample of 45 responses was analysed. Respondents had an average of 6 years’ experience in
CDS (Min:0, Max:30, SD: 6.93) and an average of 8 years’ experience in genomics (Min:0,
Max:30, SD: 5.53). The majority of CDS experience is related to research involving the use
of CDS (64%) and CDS knowledge authoring and design (58%) (see Figure 2). Delivery of
genetic information or decision support through health IT (60%) and bioinformatics/genome
informatics (44%) was the experience most described by those with genomics expertise.
Respondents represented a wide range of collaborations and workgroups, with highest
participation from the eMERGE Network (29%), the AMIA Genomic Workgroup (24%),
the AMIA CDS Workgroup (22%) and ClinGen (13%). Several respondents were involved
with multiple groups. 22% described participating in ‘Other’, (see Appendix B). 93% of the
respondents do not currently use a CDS sandbox, reinforcing the need to develop a solution.
3.1. Validation of genomic CDS Sandbox Approach
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Several questions were asked to validate the proposed genomic CDS sandbox (see
Introduction). The responses provide strong support with 93% of respondents agree (51%
strongly agree, 42% agree) with the proposed design and features of proposed genomic CDS
sandbox. In assessing the uses of a genomic CDS sandbox, roughly 80% of respondents
considered it to be ‘extremely important’ or ‘quite important’ to conduct usability and
human factors research (47% extremely, 31% quite likely); to identify gaps in standards and
technologies (47%); develop and test Genomic CDS rules and algorithms (44%); and a
quarter of respondents considered it to be ‘extremely important’ to the design and implement
novel architectural approaches (24%). See Figure 3.
Respondents placed a high importance on the availability of the genetic CDS sandbox,
namely: the genomic sandbox is freely available to download and use (60% ‘extremely
important’, 27% ‘quite important’); the outcomes and products of the sandbox are easily
transferrable to commercial EHRs (60%‘extremely important’, 27% ‘quite important’); and
uses open source products and tools (51%‘extremely important’, 27% ‘quite important’).
See Figure 4.
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In addition to these responses, participants proposed additional sandbox features including
integration with commercial EHRs, inclusion of existing CDS solutions such as Infobuttons,
and making availability of the sandbox as a downloadable solution for personal computers,
laptops and servers.20
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3.2. Usage of the genomic CDS sandbox
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Over two-thirds (67%) of respondents would be ‘extremely likely’ or ‘quite likely’ to use the
proposed genomic CDS sandbox. 71% of the respondents are currently working on/or have
future projects that will benefit from the genomic CDS sandbox. Examples of such projects
include CDS systems for genomically-guided cancer therapy, pharmacogenomics projects,
inherited disorder genomics, and ordering of molecular/genomic tests for tumors. Potential
genomic CDS sandbox users would use the genomic CDS sandbox for testing use cases in
pharmacogenomics (87%), disease risk assessment (58%), diagnostics (42%), therapeutics
(38%), disease management (36%), patient management (27%), and prenatal/newborn
screening (24%). See Figure 5. Interestingly, all respondents said they would ‘likely’ (31%
extremely, quite likely 24%) work with Standards Development Organizations such as HL7,
SNOMED, LOINC, etc. to propose new standards if they identified gaps in health IT or
genomic standards. For training and technical support for using the genomic CDS Sandbox,
of the proposed options, the majority of respondents identified user manuals (71%),
community user forums (64%), webinars (60%), video tutorials (58%) and email support
(51%), as the preferred media.
3.3. Building a Genomic CDS Sandbox Community
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We also assessed the importance of developing a community of genomics CDS sandbox
users. A majority of respondents (80%) believe that it is ‘extremely important’ or ‘quite
important’ to build and support this community of experts to facilitate innovation and
enhancements. Approximately two-third of respondents (51% extremely, 29% quite) stated
that they would be ‘extremely likely’ or ‘quite likely’ to participate in the community. The
majority of respondents said they would participate with the community using email
discussions (69%), conferences and publications (69%), and workgroup meetings (53%).

4. Discussion
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The purpose of this survey was to demonstrate the need for a genomic CDS sandbox. Our
survey results show that there is significant interest and demand for the development of a
genomic CDS sandbox. There is a general sentiment that genomic CDS sandbox is an
important need, this survey provides that data that confirms this sentiment that was first
articulated at the NHGRI conference. Furthermore, we received strong support for our
planned approach. Interestingly we found that if such a solution is available to the
community of Genomics and CDS users, there is a good chance that they will not only
utilize such a system, but also participate in a community of Genomic CDS by sharing their
experiences and promoting its use. A majority of respondents would be extremely likely to
conduct usability and human factors research on Genomic CDS interventions, and identify
gaps in standards and technologies needed for Genomic CDS. Notably, all respondents also
stated that they would likely participate in standards development if gaps in standards were
found. We identified pharmacogenomics and disease risk assessment as the biggest use cases
for users of the genomic CDS sandbox.
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4.1 Strengths and Limitations
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This survey clearly confirmed and identified needs and desires for a genomic CDS sandbox
environment from intended end users. Also the timing of this survey is quite relevant as
recent advances in genome sequencing technology have dramatically reduced the cost of
obtaining a whole genome sequence, making it less expensive and more accessible.
However, it does not reduce the complexity, which will require CDS to manage.9
Furthermore, Meaningful Use is standardizing the health IT infrastructure, making it easier
to develop and share CDS in other clinical domains. At this time it is critical to create a
collaborative effort among genomics researchers and CDS experts to address issues related
to genomic data integration with the EHRs, CDS knowledge base development, genetic test
reporting and interpretation. Developing a genomic CDS sandbox is a critical first step
toward this goal. The main limitation of the study was its relatively small sample size
(n=45). However, we received a diverse representation of responses, and results were
sufficient for our purpose of conducting this study. Additionally, results would likely not
been significantly different if sample size were increased. While there is potential for
response bias because survey respondents were selected to represent the intended users
(CDS and genomics experts) of the sandbox, our results generally reflect the current
genomic CDS trends in the industry. 14 Another limitation of this study is that the survey
instruments did not use more robust survey questionnaire validation methodology.21
However, the questions were derived and refined by a panel of genomics and CDS experts
before being distributed to the survey respondents, which we felt was sufficient for this
study.
4.2 Future Direction
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The survey was conducted as a preliminary step towards the development of a genomic CDS
sandbox. The results of this survey will guide the next steps and future direction of this
effort, including funding opportunities, strategic partners, and an optimal development
strategy. The next steps of this effort are to identify potential tools and technologies that
would be used to create the genomic CDS sandbox. First, we will need to identify potential
EHRs, personal health records, laboratory information systems, CDS tools, genome
databases, and technologies that can be used within the genomic CDS sandbox environment.
Second, we need to identify necessary resources to design and develop the genomic CDS
sandbox including technical and clinical expertise, computational resources, funding, and
other types of support. Third, potential case studies to be implemented as primary examples
for the genomic CDS sandbox need to be identified and developed. After the genomic CDS
sandbox is built, we can then distribute to users and continue to identify opportunities to
improve and expand genomic CDS capabilities based on their feedback. We will also be
including various Health IT solutions providers in future studies to identify existing
components to include in the genomic CDS sandbox. There are certainly many opportunities
for future research and development in this space. Finally, just as we used an advisory panel
to conduct this needs assessment study, we intend to create a governance committee to guide
the development and management of the genomic CDS sandbox.
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Conclusion
A genomic CDS sandbox could provide a common platform to develop, test, and evaluate
potential genomic CDS approaches and techniques. Results from this study provides strong
evidence for the need and desire of a genomic CDS sandbox from among a community of
genomics and CDS domain experts. Once built, it is anticipated that genomic CDS
approaches developed and tested using this sandbox will be utilized in the clinical setting,
improving the ability of clinicians to practice genomically-guided medicine.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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APPENDIX B: Survey Respondent's Affiliation selecting “Other” for their
Organizations
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1.

Clinical and Translational Science Award (CTSA)

2.

Bioinformatics Australia

3.

Private clinical decision support company that includes pharmacy genomic
data in the CDSS

4.

Newborn Sequencing In Genomic medicine and public Health (NSIGHT)

5.

Global Alliance for Genomics and Health (GA4GH)

6.

IOM EHR Action Collaborative

7.

East Carolina University (Academic)
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Figure 1.

Technical desiderata for WGS guided CDS from Masys et al. and Welch et al.
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Figure 2.

Involvement of survey respondents with CDS and Genomics and their affiliation
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Figure 3.

Desired features of Genomic CDS Sandbox
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Figure 4.

Features relating to Availability and use of genomic CDS sandbox
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Figure 5.

Test Case studies for Sandbox
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